Category - Feature

Feature

Transforming biologic drug discovery with Sean McClain of Absci

As CEO and founder of Absci (NASDAQ:ABSI), a drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, Sean McClain has come a long way in the...

March 15, 2022

Feature

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with...

March 8, 2022

Feature

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

Precigen (NASDAQ:PGEN) is advancing a pipeline of next generation gene and cell therapies using precision technology in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

March 1, 2022

Feature

Palisade Bio guarding against post-operative disruption of GI function

Palisade Bio (NASDAQ:PALI) is advancing therapies that help patients with acute and chronic GI complications, stemming from post-operative tissue damage, to speed recovery and reduce hospital stays.

February 22, 2022

Feature

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics (OTC:SIGY) hopes to file in the second quarter this year an investigational device exemption (IDE) with the FDA to initiate human clinical studies of its Sigyn Therapy, a dual-function blood...

February 15, 2022

Feature

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Athira Pharma (NASDAQ:ATHA) is in late- and mid-stage clinical development of small molecules to restore neuronal health and slow neurodegeneration of diseases, such as Alzheimer’s, Parkinson’s and dementia.

February 8, 2022

Feature

Zucara awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes

Closely held Zucara Therapeutics expects to release results in the second quarter of its Phase 1b proof-of-concept study with its once-daily drug candidate, ZT-01, to prevent insulin-induced hypoglycemia, or low blood...

February 1, 2022

Feature

Aravive developing targeted cancer therapeutics to treat metastatic disease

Aravive (NASDAQ:ARAV) is taking a differentiated approach with its lead molecule, batiraxcept, to target inhibition of the GAS6/AXL signaling pathway in several cancer indications.

January 25, 2022

Feature

POINT Biopharma creating platform for next-generation radiopharmaceuticals

POINT Biopharma Global (NASDAQ:PNT) is accelerating the development of precision medicines for the treatment of cancer, with a late- and early-stage pipeline of radiopharmaceuticals, a technology platform for pipeline...

January 18, 2022

Feature

ENDRA’s TAEUS enhancing ultrasound to measure fatty liver disease NAFLD-NASH

ENDRA Life Sciences (NASDAQ:NDRA) has developed a novel assessment tool – Thermo Acoustic Enhanced Ultrasound (TAEUS) – to enhance existing ultrasound systems and provide capabilities that are available with MRI, but at...

January 11, 2022

Category - Feature

Subscribe